🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Tarsus Pharmaceuticals, Inc.

TARS Healthcare
$69.2 +$0.32 (0.46%)
Market Cap: $3.04 B
Gurus Holding
5
Popularity Rank
#2012
% of Shares Held
0.46%
Net Activity (Q2 2026)
-$18.31 M

Guru Ownership Trend

Guru Analysis for Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. (TARS), a key player in the Healthcare sector, continues to attract institutional attention.

As of Q1 2026, a total of 5 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $13.89 M.

Top institutional holders include Jefferies Group and Cliff Asness.

Institutional sentiment is currently Slightly Bearish. This is evidenced by a $18.31 M net outflow during the quarter.

Recent activity highlights Paul Tudor Jones who opened a new position. Conversely, Renaissance Technologies (RenTech) reduced exposure by 87.3%.

Key Holders

Recent Activity Breakdown (Q2 2026)

+$1.59 M
Total Buy Value
New Buys 1
Additions 2
-$19.91 M
Total Sell Value
Reductions 1
Sold Out 1

Guru Consensus (Q2 2026)

Based on recent activity
Net Sellers
2
Net Buyers
3

FAQs for Tarsus Pharmaceuticals, Inc. (TARS)

Major holders include Jefferies Group ($8.33 M), Cliff Asness ($2.64 M), John Hussman ($1.32 M). According to the latest reported data, 5 tracked investment managers collectively hold approximately 200,654 shares.

According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $18.31 M, with 3 managers increasing positions and 2 managers reducing holdings.

During the most recent reporting period, 1 managers trimmed their positions, while 1 fully exited TARS. The total reported sell value was $19.91 M.

Yes, 1 managers opened new positions in TARS, and 2 increased their existing holdings. The total reported buy value was $1.59 M.

Portfolio Manager % Portfolio Activity Shares Value Report Date
0.06% 118,810 $8.33 M Q1 2026
0.00% Add 37.9% 42,003 $2.64 M Q2 2026
0.30% Add 25.0% 21,000 $1.32 M Q2 2026
0.00% New Buy 9,541 $600,511 Q2 2026
0.00% Reduce -87.3% 9,300 $585,342 Q2 2026
Date
Insider Name
Transaction
Value
Shares
Position / Chg
SEC Form